Clinical Trials Logo

MTD: Soft Tissue Sarcomas clinical trials

View clinical trials related to MTD: Soft Tissue Sarcomas.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00878800 Completed - Clinical trials for MTD: Soft Tissue Sarcomas

A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas

Start date: December 2006
Phase: Phase 1/Phase 2
Study type: Interventional

Open-label, multicentre, dose-escalation Phase I/II study to evaluate safety, efficacy, pharmacodynamics, and pharmacokinetics of the combination of PXD101 with doxorubicin administered q 3 weeks in patients with advanced solid tumours. Once the Maximum Tolerable Dose has been established, up to a total of 20-40 patients with Soft Tissue Sarcoma may be enrolled at the MTD dose level to examine efficacy and safety in this specific patient population. The trial is stopped if no more than 2 responses are seen among the first 20 of these patients.